earnings
confidence high
sentiment positive
materiality 0.85
PDS Biotech Q2 net loss narrows to $8.3M; FDA aligned on Phase 3 trial for Versamune HPV in HNSCC
PDS Biotechnology Corp
2024-Q2 EPS reported
-$0.53
- Net loss $8.3M ($0.23/share) vs $11.5M ($0.37/share) YoY; R&D expenses down 44% to $4.5M.
- Cash and equivalents $57.7M as of June 30, 2024.
- FDA alignment achieved on Phase 3 VERSATILE-003 trial design for Versamune HPV + pembrolizumab; start Q4 2024.
- Updated VERSATILE-002 data shows median OS of 30 months; abstracts accepted at ESMO, ASTRO, ICIS 2024.
- Total operating expenses reduced to $8.7M from $12.7M YoY.